Press releases
- Silence Therapeutics to Present at Jefferies Global Healthcare Conference
- Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
- Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
- Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
More ▼
Key statistics
On Friday, Silence Therapeutics PLC (SLN:NMQ) closed at 20.99, -24.28% below its 52-week high of 27.72, set on Mar 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.81 |
---|---|
High | 22.34 |
Low | 20.75 |
Bid | 20.60 |
Offer | 23.24 |
Previous close | 21.81 |
Average volume | 86.82k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼